Trexquant Investment LP Buys Shares of 265,046 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Trexquant Investment LP purchased a new stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 265,046 shares of the company’s stock, valued at approximately $3,901,000. Trexquant Investment LP owned about 0.39% of Amylyx Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Amylyx Pharmaceuticals by 16.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,134 shares of the company’s stock worth $112,000 after acquiring an additional 859 shares during the period. China Universal Asset Management Co. Ltd. lifted its stake in shares of Amylyx Pharmaceuticals by 351.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,815 shares of the company’s stock valued at $115,000 after purchasing an additional 6,085 shares during the period. Arizona State Retirement System bought a new stake in shares of Amylyx Pharmaceuticals during the 4th quarter valued at about $166,000. Handelsbanken Fonder AB acquired a new stake in Amylyx Pharmaceuticals during the fourth quarter worth approximately $175,000. Finally, AXQ Capital LP bought a new stake in Amylyx Pharmaceuticals in the third quarter worth approximately $198,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX opened at $1.78 on Friday. Amylyx Pharmaceuticals, Inc. has a 52 week low of $1.70 and a 52 week high of $27.49. The stock has a 50 day moving average price of $2.24 and a two-hundred day moving average price of $10.34.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Friday, May 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.70). The company had revenue of $88.64 million for the quarter, compared to the consensus estimate of $113.26 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a positive return on equity of 4.14%. During the same quarter last year, the business posted $0.02 earnings per share. On average, equities analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.36 earnings per share for the current year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 1,792 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $18.73, for a total value of $33,564.16. Following the completion of the sale, the chief financial officer now owns 134,784 shares in the company, valued at approximately $2,524,504.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Amylyx Pharmaceuticals news, CFO James M. Frates sold 1,792 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $33,564.16. Following the completion of the transaction, the chief financial officer now owns 134,784 shares in the company, valued at approximately $2,524,504.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Joshua B. Cohen sold 4,135 shares of Amylyx Pharmaceuticals stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $77,448.55. Following the sale, the chief executive officer now owns 3,023,002 shares in the company, valued at $56,620,827.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,922 shares of company stock worth $159,512. 11.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on AMLX. Robert W. Baird downgraded shares of Amylyx Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research report on Monday, March 11th. SVB Leerink lowered shares of Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Monday, March 11th. HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of Amylyx Pharmaceuticals in a research note on Friday, May 10th. Mizuho decreased their target price on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, May 14th. Finally, The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.67.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.